Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation

Daru

Volumn 18, Issue 2, 2010, Pages 84-90

  Nakarani, M ^a   Misra, Ambikanandan N ^b   Patel, J K ^c   Vaghani, S S ^d  

^a Unison pharmaceuticals ^*  (India)

^b M S UNIVERSITY OF BARODA   (India)

^c NOOTAN PHARMACY COLLEGE   (India)

^d Smt R B Patel Mahila Pharmacy College   (India)

Author keywords

Itraconazole; Nanosuspension; Pearl milling technique

Indexed keywords

GLYCEROL; HYDROCHLORIC ACID; ITRACONAZOLE; MANNITOL; POLOXAMER; ZIRCONIUM OXIDE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; FREEZE DRYING; IN VITRO STUDY; NANOFABRICATION; PARTICLE SIZE; PROCESS OPTIMIZATION; SCANNING ELECTRON MICROSCOPY; SUSPENSION; X RAY DIFFRACTION;

EID: 77954823457     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother, 1988; 32:1-8.
2. Odds FC, Oris M, Dorsselaer PV, Gerven FV. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections. Antimicrob Agents Chemother, 2000; 44:3180-3183.
3. Fromtling RA. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona, Spain, J.R. Prous Science Publishers, 1987; 233-249.
4. Barratt GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Tech Today, 2000; 3:163-169.
5. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailablility. Pharm Res, 1995; 12:413-420.
6. Maeda T, Takenaka H, Yamahira Y, Noguchi T. Use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets. J Pharm Sci, 1979; 68:1286-1289.
7. Chiba Y, Kohri N, Iseki K, Miyazaki K. Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol. Chem Pharm Bull, 1991; 39:2158-2160.
8. Liversidge ME, Sarpotdar P, Bruno J, Hajj S, Wel L. et al. Formulation and antitumor evaluation of nano crystalline suspensions of poorly soluble anticancer drug. Pharm Res, 1996; 13:272-278.
9. Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm, 1997; 160:229-237.
10. Westesen K, Siekmann B. Preparation and physicochemical characterization of aqueous dispersions of coenzyme Q10 nanoparticles. Pharm Res, 1995; 12:201-208.
11. Muller RH. In vivo distribution of carriers. In: Colloidal Carriers for Controlled Drug Delivery and Targeting. Boca Raton, FL, CRC Press inc. 1991; 211-274.
12. Mishra B, Arya N, Tiwari S. Investigation of formulation variables affecting the properties of lamotrigine nanosuspension using factorial design. DARU, 2010;18(1):1-8.
13. Guo J, Ping Q, Chen Y. Pharmacokinetic behavior of Cyclosporine A in rabbits by oral administration of lecithin vesicle and sandimmun neoral. Int J Pharm, 2001; 216:17-21.
14. Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimization and longterm stability. Int J Pharm, 2002; 237:151-61.
15. Teeranachaideekul V, Junyaprasert VB, Souto EB, Muller RH. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int J Pharm, 2008; 354:227-234.
16. Muller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 2001; 47:3-19.